{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:36:16Z","timestamp":1792571776307,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences & health services","doi-asserted-by":"crossref","award":["1401-3-221-63420"],"award-info":[{"award-number":["1401-3-221-63420"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-026-01713-w","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:13:38Z","timestamp":1778120018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of metformin on bone turnover markers: a systematic review and meta-analysis of clinical trials"],"prefix":"10.1007","volume":"21","author":[{"given":"Mohammadreza","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Mirdamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Khashayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-9721","authenticated-orcid":false,"given":"Ozra","family":"Tabatabaei-Malazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Golabchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"khashayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"2","key":"1713_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ecl.2022.10.009","volume":"52","author":"S Khandelwal","year":"2023","unstructured":"Khandelwal S, Lane NE (2023) Osteoporosis: review of etiology, mechanisms, and approach to management in the aging population. Endocrinol Metab Clin North Am 52(2):259\u2013275","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1713_CR2","unstructured":"Epidemiology of osteoporosis and fragility fractures. International Osteoporosis Foundation. Available from: https:\/\/www.osteoporosis.foundation\/facts-statistics\/epidemiology-of-osteoporosis-and-fragility-fractures. Accessed 02 May 2026"},{"issue":"1","key":"1713_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13697137.2021.1965408","volume":"25","author":"TJ de Villiers","year":"2022","unstructured":"de Villiers TJ, Goldstein SR (2022) Bone health 2022: an update. Climacteric 25(1):1\u20133. https:\/\/doi.org\/10.1080\/13697137.2021.1965408","journal-title":"Climacteric"},{"key":"1713_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2043479","volume":"2021","author":"V Povoroznyuk","year":"2021","unstructured":"Povoroznyuk V, Grygorieva N, Johansson H, Lorentzon M, Harvey NC, McCloskey EV et al (2021) FRAX-based intervention thresholds for osteoporosis treatment in Ukraine. J Osteoporos 2021:2043479. https:\/\/doi.org\/10.1155\/2021\/2043479","journal-title":"J Osteoporos"},{"issue":"2","key":"1713_CR5","doi-asserted-by":"publisher","first-page":"153.e1","DOI":"10.1016\/j.jhsa.2019.01.018","volume":"45","author":"AN Mora","year":"2020","unstructured":"Mora AN, Blazar PE, Rogers JC, Earp BE (2020) Patient perceptions and preferences for osteoporosis treatment. J Hand Surg Am 45(2):153.e1-.e5. https:\/\/doi.org\/10.1016\/j.jhsa.2019.01.018","journal-title":"J Hand Surg Am"},{"key":"1713_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2147\/cia.S242288","volume":"15","author":"EE Nagy","year":"2020","unstructured":"Nagy EE, Nagy-Finna C, Popoviciu H, Kov\u00e1cs B (2020) Soluble biomarkers of osteoporosis and osteoarthritis, from pathway mapping to clinical trials: an update. Clin Interv Aging 15:501\u2013518. https:\/\/doi.org\/10.2147\/cia.S242288","journal-title":"Clin Interv Aging"},{"key":"1713_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.585689","volume":"11","author":"S Marini","year":"2020","unstructured":"Marini S, Barone G, Masini A, Dallolio L, Bragonzoni L, Longobucco Y et al (2020) The effect of physical activity on bone biomarkers in people with osteoporosis: a systematic review. Front Endocrinol (Lausanne) 11:585689. https:\/\/doi.org\/10.3389\/fendo.2020.585689","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1713_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065814","author":"LT Wang","year":"2023","unstructured":"Wang LT, Chen LR, Chen KH (2023) Hormone-related and drug-induced osteoporosis: a cellular and molecular overview. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065814","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1713_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16(8):437\u2013447. https:\/\/doi.org\/10.1038\/s41574-020-0341-0","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"1713_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","volume":"20","author":"M Foretz","year":"2014","unstructured":"Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20(6):953\u201366. https:\/\/doi.org\/10.1016\/j.cmet.2014.09.018","journal-title":"Cell Metab"},{"key":"1713_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020122","author":"J Drzewoski","year":"2021","unstructured":"Drzewoski J, Hanefeld M (2021) The current and potential therapeutic use of Metformin-the good old drug. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14020122","journal-title":"Pharmaceuticals (Basel)"},{"key":"1713_CR12","doi-asserted-by":"publisher","unstructured":"Karagoz ZK, Sahin I, Kurt F, Ozgur Cil B (2022) Evaluation of the effect of metformin treatment on markers of bone formation and resorption in patients newly diagnosed with type 2 diabetes. Med Sci 11(4). https:\/\/doi.org\/10.5455\/medscience.2022.02.033","DOI":"10.5455\/medscience.2022.02.033"},{"issue":"2","key":"1713_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.fertnstert.2019.04.013","volume":"112","author":"S Lingaiah","year":"2019","unstructured":"Lingaiah S, Morin-Papunen L, Risteli J, Tapanainen JS (2019) Metformin decreases bone turnover markers in Polycystic Ovary Syndrome: a post hoc study. Fertil Steril 112(2):362\u2013370. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.04.013","journal-title":"Fertil Steril"},{"issue":"2","key":"1713_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1210\/er.2012-1042","volume":"36","author":"MP Gilbert","year":"2015","unstructured":"Gilbert MP, Pratley RE (2015) The impact of diabetes and diabetes medications on bone health. Endocr Rev 36(2):194\u2013213. https:\/\/doi.org\/10.1210\/er.2012-1042","journal-title":"Endocr Rev"},{"issue":"6","key":"1713_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072904","volume":"13","author":"J Hu","year":"2023","unstructured":"Hu J, Han J, Jin M, Jin J, Zhu J (2023) Effects of Metformin on bone mineral density and bone turnover markers: a systematic review and meta-analysis. BMJ Open 13(6):e072904. https:\/\/doi.org\/10.1136\/bmjopen-2023-072904","journal-title":"BMJ Open"},{"key":"1713_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59050904","author":"RD Chen","year":"2023","unstructured":"Chen RD, Yang CW, Zhu QR, Li Y, Hu HF, Wang DC et al (2023) Comparison of the effects of Metformin and thiazolidinediones on bone metabolism: a systematic review and meta-analysis. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina59050904","journal-title":"Medicina (Kaunas)"},{"key":"1713_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147988","author":"MSS Saadi","year":"2024","unstructured":"Saadi MSS, Das R, Mullath UA, Powell DE, Wilson E, Myrtziou I et al (2024) Impact of different anti-hyperglycaemic treatments on bone turnover markers and bone mineral density in Type 2 Diabetes Mellitus patients: a systematic review and meta-analysis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25147988","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1713_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1515\/cclm-2024-1148","volume":"63","author":"G Lombardi","year":"2025","unstructured":"Lombardi G, J\u00f8rgensen NR, Harvey NC, McCloskey EV, \u00c5kesson KE, Eastell R et al (2025) Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone Metabolism. Clin Chem Lab Med 63(4):704\u201311. https:\/\/doi.org\/10.1515\/cclm-2024-1148","journal-title":"Clin Chem Lab Med"},{"key":"1713_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"1","key":"1713_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"key":"1713_CR21","unstructured":"Higgins JP (2019) Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Available: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.0"},{"issue":"5","key":"1713_CR22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1365-2753.2008.00986.x","volume":"14","author":"JP Ioannidis","year":"2008","unstructured":"Ioannidis JP (2008) Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract 14(5):951\u2013957. https:\/\/doi.org\/10.1111\/j.1365-2753.2008.00986.x","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"1713_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1210\/jc.2009-0572","volume":"95","author":"B Zinman","year":"2010","unstructured":"Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG et al (2010) Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 95(1):134\u201342. https:\/\/doi.org\/10.1210\/jc.2009-0572","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1713_CR24","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1463-1326.2011.01461.x","volume":"13","author":"JL Borges","year":"2011","unstructured":"Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ et al (2011) A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone\/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-na\u00efve type 2 diabetes mellitus patients. Diabetes Obes Metab 13(11):1036\u201346. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01461.x","journal-title":"Diabetes Obes Metab"},{"key":"1713_CR25","doi-asserted-by":"publisher","DOI":"10.1210\/endo-meetings.2011.part3.p23.p3-121","author":"VW Harris","year":"2011","unstructured":"Harris VW, McComsey G, Chen H, Deng L, Yin M, Cremers S et al (2011) The effects of rosiglitazone and metformin on longitudinal changes in bone mineral density and bone turnover markers in non-diabetic HIV-infected persons with lipodystrophy: a secondary analysis of AIDS Clinical Trial Group (ACTG) A5082. Endocr Rev. https:\/\/doi.org\/10.1210\/endo-meetings.2011.part3.p23.p3-121","journal-title":"Endocr Rev"},{"key":"1713_CR26","unstructured":"Agarwal S, Rubin M, Manavalan S, McMahon D, Nino A, Fitzpatrick L et al (2012) Rosiglitazone affects osteoclast activity in type 2 diabetes mellitus. J Bone Miner Res 27(Suppl 1). Available at: https:\/\/www.asbmr.org\/meetings\/2012-abstracts. Accessed 04 Feb 2026"},{"issue":"11","key":"1713_CR27","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","volume":"14","author":"\u00d6 Ljunggren","year":"2012","unstructured":"Ljunggren \u00d6, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sj\u00f6str\u00f6m CD et al (2012) Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 14(11):990\u20139. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01630.x","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1713_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1530\/eje-11-1061","volume":"166","author":"AH van Lierop","year":"2012","unstructured":"van Lierop AH, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ et al (2012) Distinct effects of Pioglitazone and Metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 166(4):711\u20136. https:\/\/doi.org\/10.1530\/eje-11-1061","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1713_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2012-4018","volume":"98","author":"JP Bilezikian","year":"2013","unstructured":"Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M et al (2013) Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 98(4):1519\u201328. https:\/\/doi.org\/10.1210\/jc.2012-4018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1713_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1055\/s-0034-1395652","volume":"47","author":"E Soifer","year":"2015","unstructured":"Soifer E, Gavish D, Shargorodsky M (2015) Does Metformin treatment influence bone formation in patients with nonalcoholic fatty liver disease? Horm Metab Res 47(8):556\u2013559. https:\/\/doi.org\/10.1055\/s-0034-1395652","journal-title":"Horm Metab Res"},{"issue":"11","key":"1713_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2169\/internalmedicine.56.8096","volume":"56","author":"H Mori","year":"2017","unstructured":"Mori H, Okada Y, Tanaka Y (2017) The effects of Pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus. Intern Med 56(11):1301\u20131306. https:\/\/doi.org\/10.2169\/internalmedicine.56.8096","journal-title":"Intern Med"},{"key":"1713_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bone.2018.04.004","volume":"112","author":"TB Stage","year":"2018","unstructured":"Stage TB, Christensen MH, J\u00f8rgensen NR, Beck-Nielsen H, Br\u00f8sen K, Gram J et al (2018) Effects of Metformin, Rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. Bone 112:35\u201341. https:\/\/doi.org\/10.1016\/j.bone.2018.04.004","journal-title":"Bone"},{"issue":"2","key":"1713_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00223-020-00711-5","volume":"107","author":"AK Nordklint","year":"2020","unstructured":"Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, J\u00f8rgensen NR, Boesgaard TW et al (2020) Effect of Metformin vs. placebo in combination with insulin analogues on bone markers P1NP and CTX in patients with type 2 diabetes mellitus. Calcif Tissue Int 107(2):160\u20139. https:\/\/doi.org\/10.1007\/s00223-020-00711-5","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"1713_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/s2213-8587(20)30021-8","volume":"8","author":"I Pernicova","year":"2020","unstructured":"Pernicova I, Kelly S, Ajodha S, Sahdev A, Bestwick JP, Gabrovska P et al (2020) Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: A randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol 8(4):278\u201391. https:\/\/doi.org\/10.1016\/s2213-8587(20)30021-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1713_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/jdi.13340","volume":"12","author":"M Koshizaka","year":"2021","unstructured":"Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D et al (2021) Effects of Ipragliflozin versus Metformin in combination with Sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study). J Diabetes Investig 12(2):200\u20136. https:\/\/doi.org\/10.1111\/jdi.13340","journal-title":"J Diabetes Investig"},{"key":"1713_CR36","doi-asserted-by":"publisher","unstructured":"Jin X, Wang Z, Zhang B, Yu J, Guan Z, Shang C et al (2025) Effects of metformin and denosumab on bone and glucose metabolism in postmenopausal women with osteoporosis and diabetes. J Endocrinol 266(3). https:\/\/doi.org\/10.1530\/JOE-25-0081","DOI":"10.1530\/JOE-25-0081"},{"issue":"5","key":"1713_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2337\/dc24-2039","volume":"48","author":"S Thierry","year":"2025","unstructured":"Thierry S, Peterson CJ, Pfammatter S, Tardio PA, Meier C, Delko T et al (2025) Short-term metformin protects against glucocorticoid-induced toxicity in healthy individuals: a randomized, double-blind, placebo-controlled trial. Diabetes Care 48(5):719\u201327. https:\/\/doi.org\/10.2337\/dc24-2039","journal-title":"Diabetes Care"},{"issue":"43","key":"1713_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000035191","volume":"102","author":"YK Wei","year":"2023","unstructured":"Wei YK, Chen PB, Ju LL, Deng GH (2023) Causal association of metformin and osteoporosis: a 2-sample Mendelian randomization study. Medicine (Baltimore) 102(43):e35191. https:\/\/doi.org\/10.1097\/md.0000000000035191","journal-title":"Medicine (Baltimore)"},{"key":"1713_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-201","volume":"11","author":"G Wheater","year":"2013","unstructured":"Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM (2013) The clinical utility of bone marker measurements in osteoporosis. J Transl Med 11:201. https:\/\/doi.org\/10.1186\/1479-5876-11-201","journal-title":"J Transl Med"},{"key":"1713_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0097-4","volume":"5","author":"TR Kuo","year":"2017","unstructured":"Kuo TR, Chen CH (2017) Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res 5:18. https:\/\/doi.org\/10.1186\/s40364-017-0097-4","journal-title":"Biomark Res"},{"issue":"4","key":"1713_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"HP Bhattoa","year":"2025","unstructured":"Bhattoa HP, Vasikaran S, Trifonidi I, Kapoula G, Lombardi G, J\u00f8rgensen NR et al (2025) Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int 36(4):579\u2013608. https:\/\/doi.org\/10.1007\/s00198-025-07422-3","journal-title":"Osteoporos Int"},{"issue":"1","key":"1713_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00966-5","volume":"20","author":"X Xie","year":"2022","unstructured":"Xie X, Hu L, Mi B, Xue H, Hu Y, Panayi AC et al (2022) Metformin alleviates bone loss in ovariectomized mice through inhibition of autophagy of osteoclast precursors mediated by E2F1. Cell Commun Signal 20(1):165. https:\/\/doi.org\/10.1186\/s12964-022-00966-5","journal-title":"Cell Commun Signal"},{"issue":"6","key":"1713_CR43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11914-023-00828-0","volume":"21","author":"TJ de Vries","year":"2023","unstructured":"de Vries TJ, Kleemann AS, Jin J, Schoenmaker T (2023) The differential effect of metformin on osteocytes, osteoblasts, and osteoclasts. Curr Osteoporos Rep 21(6):743\u2013749. https:\/\/doi.org\/10.1007\/s11914-023-00828-0","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"1713_CR44","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbrc.2008.08.034","volume":"375","author":"I Kanazawa","year":"2008","unstructured":"Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375(3):414\u2013419. https:\/\/doi.org\/10.1016\/j.bbrc.2008.08.034","journal-title":"Biochem Biophys Res Commun"},{"key":"1713_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100330","volume":"24","author":"P Sharma","year":"2024","unstructured":"Sharma P, Sharma RK, Gaur K (2024) Understanding the impact of diabetes on bone health: a clinical review. Metab Open 24:100330. https:\/\/doi.org\/10.1016\/j.metop.2024.100330","journal-title":"Metab Open"},{"issue":"1","key":"1713_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01518-2","volume":"16","author":"P Khashayar","year":"2024","unstructured":"Khashayar P, Rad FF, Tabatabaei-Malazy O, Golabchi SM, Khashayar P, Mohammadi M et al (2024) Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials\u2019 meta-analysis studies. Diabetol Metab Syndr 16(1):310. https:\/\/doi.org\/10.1186\/s13098-024-01518-2","journal-title":"Diabetol Metab Syndr"},{"issue":"18","key":"1713_CR47","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.12998\/wjcc.v8.i18.4010","volume":"8","author":"LX Wang","year":"2020","unstructured":"Wang LX, Wang GY, Su N, Ma J, Li YK (2020) Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 diabetes mellitus. World J Clin Cases 8(18):4010\u20134016. https:\/\/doi.org\/10.12998\/wjcc.v8.i18.4010","journal-title":"World J Clin Cases"},{"issue":"5","key":"1713_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101350","volume":"48","author":"J Sun","year":"2022","unstructured":"Sun J, Liu Q, He H, Jiang L, Lee KO, Li D et al (2022) Metformin treatment is associated with an increase in bone mineral density in type 2 diabetes mellitus patients in China: a retrospective single center study. Diabetes Metab 48(5):101350. https:\/\/doi.org\/10.1016\/j.diabet.2022.101350","journal-title":"Diabetes Metab"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01713-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01713-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:13:42Z","timestamp":1778120022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01713-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01713-w","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committees of Endocrine and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.EMRI.REC.1401.074).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"During the preparation of this work the authors used GPT-4 in order to check grammar and improve readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI in scientific writing"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"78"}}